Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) has been given an average recommendation of “Buy” by the six analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $32.75.
YMAB has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Protalix Biotherapeutics in a research note on Monday, June 10th. Cowen reaffirmed a “buy” rating on shares of Ovid Therapeutics in a report on Monday, July 1st. Finally, Zacks Investment Research raised ZovioInc . from a “sell” rating to a “hold” rating in a report on Sunday.
Shares of NASDAQ:YMAB traded up $0.09 during trading on Wednesday, reaching $22.96. 1,130 shares of the stock were exchanged, compared to its average volume of 235,489. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.30 and a current ratio of 13.30. Y-mAbs Therapeutics has a 1-year low of $15.17 and a 1-year high of $31.00. The stock has a fifty day moving average price of $21.82. The stock has a market capitalization of $782.01 million and a price-to-earnings ratio of -15.27.
Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.07). Equities analysts anticipate that Y-mAbs Therapeutics will post -1.95 earnings per share for the current fiscal year.
In other news, insider Thomas Gad sold 4,000 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $22.40, for a total value of $89,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 28,000 shares of company stock worth $592,880 over the last three months. Corporate insiders own 38.40% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in YMAB. TD Asset Management Inc. boosted its stake in shares of Y-mAbs Therapeutics by 24.1% in the first quarter. TD Asset Management Inc. now owns 22,829 shares of the company’s stock worth $598,000 after acquiring an additional 4,432 shares during the period. Bank of America Corp DE increased its holdings in Y-mAbs Therapeutics by 3,056.5% during the 4th quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after purchasing an additional 5,838 shares during the period. American International Group Inc. purchased a new position in Y-mAbs Therapeutics during the 4th quarter worth $93,000. Barclays PLC purchased a new position in Y-mAbs Therapeutics during the 4th quarter worth $210,000. Finally, BNP Paribas Arbitrage SA purchased a new position in Y-mAbs Therapeutics during the 1st quarter worth $38,000. 24.80% of the stock is owned by institutional investors and hedge funds.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Read More: Oversold
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.